ArticleInternational journal of rheumatology2012
Immunosuppressive exosomes: a new approach for treating arthritis.
Article in International journal of rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 87 citations in OpenAlex.
- Therapeutic application of extracellular vesicles in human diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- The Role of Extracellular Vesicles in Bone Regeneration and Associated Bone Diseases.Current issues in molecular biology · 2024Review
- Exosomes and exosomal miRNAs: A new avenue for the future treatment of rheumatoid arthritis.Heliyon · 2024Review
- Exosome-mediated delivery of super-repressor IκBα alleviates inflammation and joint damages in rheumatoid arthritis.Arthritis research & therapy · 2024Article
- Intrathecal administration of conditioned serum from different species resolves Chemotherapy-Induced neuropathic pain in mice via secretory exosomes.Brain, behavior, and immunity · 2023Article
- Adipose Tissue-Derived Extracellular Vesicles: A Promising Biomarker and Therapeutic Strategy for Metabolic Disorders.Stem cells international · 2023Review
- Exosome application in treatment and diagnosis of B-cell disorders: leukemias, multiple sclerosis, and arthritis rheumatoid.Cellular & molecular biology letters · 2022Review
- Characteristics of Extracellular Vesicles and Preclinical Testing Considerations Prior to Clinical Applications.Biomedicines · 2022Review
- Harnessing the Therapeutic Potential of Extracellular Vesicles for Biomedical Applications Using Multifunctional Magnetic Nanomaterials.Small (Weinheim an der Bergstrasse, Germany) · 2022Review
- Immunomodulatory matrix-bound nanovesicles mitigate acute and chronic pristane-induced rheumatoid arthritis.NPJ Regenerative medicine · 2022Article
- Extracellular Vesicles Derived FromFrontiers in immunology · 2022Article
- Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome.PloS one · 2022Article
- Circulating extracellular vesicles and rheumatoid arthritis: a proteomic analysis.Cellular and molecular life sciences : CMLS · 2021Review
- The Role of Cell Organelles in Rheumatoid Arthritis with Focus on Exosomes.Biological procedures online · 2021Review
- Toxic and Teratogenic Effects of Prenatal Alcohol Exposure on Fetal Development, Adolescence, and Adulthood.International journal of molecular sciences · 2021Review
- Ancient Evolutionary Origin and Properties of Universally Produced Natural Exosomes Contribute to Their Therapeutic Superiority Compared to Artificial Nanoparticles.International journal of molecular sciences · 2021Review
- The Role of Non-Immune Cell-Derived Extracellular Vesicles in Allergy.Frontiers in immunology · 2021Review
- Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments.Immunological investigations · 2020Article
- Milk-Derived Extracellular Vesicles in Inter-Organism, Cross-Species Communication and Drug Delivery.Proteomes · 2020Review
- Emerging Roles of Exosomes in T1DM.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease and one of the leading causes of disability in the USA. Although certain biological therapies, including protein and antibodies targeting inflammatory factors such as the tumor necrosis factor, are effective in reducing symptoms of RA, these treatments do not reverse disease. Also, although novel gene therapy approaches have shown promise in preclinical and clinical studies to treat RA, it is still unclear whether gene therapy can be readily and safely applied to treat the large number of RA patients. Recently, nanosized, endocytic-derived membrane vesicles "exosomes" were demonstrated to function in cell-to-cell communication and to possess potent immunoregulatory properties. In particular, immunosuppressive DC-derived exosomes and blood plasma- or serum-derived exosomes have shown potent therapeutic effects in animal models of inflammatory and autoimmune disease including RA. This paper discusses the current knowledge on the production, efficacy, mechanism of action, and potential therapeutic use of immunosuppressive exosomes for arthritis therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.